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ABSTRACT
Objective: To determine the prevalence of hospital admissions for adverse drug reaction 
(ADR) in Salvador, Bahia, and their outcome. Methods: All patients admitted to the four 
Sentinel Hospitals of Anvisa in Salvador, Ba, from April to December 2007 were evalu-
ated and followed-up to determine the prevalence of admissions due to ADR and their 
outcomes. Cases were validated by three algorithms. The drugs were classified by the 
Anatomical-Therapeutic-Chemical Classification, organs and systems affected accord-
ing to WHO criteria, and severity according to Pearson et al. Type of ADR was analyzed 
according to Rawlins and Thompson criteria.Results: The prevalence of ADR admis-
sions was 0.56% and the prevalence adjusted (exposed) was 2.1%, with 316 cases. Mean 
hospitalization time due to ADR was 12.3 days. Young and elderly patients accounted for 
28.8% and 31.1%, respectively. Females and blacks corresponded to 60% of cases. The 
main pharmacologic groups involved were antineoplastics, antibiotics, and diuretics, 
affecting skin, gastrointestinal, and hematologic systems. Approximately 70% of ADRs 
were validated as defined. Eighty per cent of the cases were ADR type A; recovery was 
observed in 90% of cases, and only one death was observed. Conclusion: The prevalence 
of ADR admission was similar to those described in literature, and only one patient died. 
As this is the first national study, it will serve as the basis for future investigations.
Keywords: Adverse drug reaction reporting systems; pharmacoepidemiology; hospital-
ization; prevalence.
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INTRODUCTION
In general, hospital admissions due to adverse drug reac-
tions (ADRs) have been a constant source of concern for 
health policy makers. Adverse drug reactions may be re-
sponsible for deaths and a significant increase in health 
costs due to prolonged hospitalizations1,2.
The first study describing the frequency of hospitaliza-
tion due to ADRs was conducted in two Belfast hospitals 
between 1965 and 1966, with a hospitalization frequency 
due to ADRs of 2.9% (37/1,268)3. In a university hospital 
in Chile, between March 1972 and March 1976, a frequen-
cy of 2.7% (53/1,958) of hospitalizations due to ADRs and 
0.1% of deaths was observed4. In two general hospitals in 
the United Kingdom, between November 2001 and April 
2002, a prevalence of 6.5% (1,125/18,820) of ADR hospi-
talizations was observed5. In Brazil, in 1999, in an inter-
nal medicine ward of a university hospital in Campinas, 
a prevalence of 6.6% (9/135) was observed6. The scarcity 
of national studies on hospitalizations due to ADRs and 
the lack of knowledge regarding morbidity and mortality 
profiles related to these reactions, along with the availabil-
ity and indiscriminate use of drugs  highlight the need for 
more studies that will contribute for planning and formu-
lation of public health policies in this field3. The objective 
of the present study was to determine the prevalence of 
hospitalizations due to ADRs and their outcome in hospi-
tals in Salvador, Bahia, Brazil.
METHODS
An observational prospective study was conducted from 
April to December 2007 in four teaching hospitals that 
compose the Rede de Hospitais Sentinela da Agência Na-
cional de Vigilância Sanitária (Anvisa), in Salvador, Bahia, 
Brazil, to determine the prevalence of hospitalizations due 
to ADRs. Two of these hospitals are public and two are 
philanthropic, and they are all reference hospitals for the 
Brazilian Unified Health System in the state — Sistema 
Único de Saúde (SUS). Patients who were hospitalized for 
an ADR were followed-up until discharge from hospital to 
analyze morbidity and mortality rates, length of hospital-
ization, and ADR-related sequelae.
In weekly meetings, all ADR-related hospitalizations 
were reviewed by a group of pharmacovigilance specialists 
to validate the causality by applying the Naranjo7, WHO8, 
and European Union8 Algorithms. Drugs responsible for 
ADRs were classified according to the Anatomical-Ther-
apeutic-Chemical Classification Index (ATC, 1997)9. Af-
fected organs and systems were classified by WHO cri-
teria, the WHOART10. Type of reaction was analyzed by 
Rawlins and Thompson criteria (1991)11.
Data on hospitalized patients due to ADRs were re-
corded in a databank and reviewed using the SPSS for Win-
dows version 10.0 soware12. Descriptive simple frequency 
analysis was used to determine the even prevalence, drugs 
and reactions more commonly involved, as well as their 
outcome. For analysis of overall prevalence, cases of ADR 
hospitalizations represented the numerator and the total 
number of admission the denominator. Adjusted preva-
lence was calculated based on patients exposed, i.e., those 
whose cause of hospitalization was not elective surgeries.
The determination of length of hospitalization for 
ADRs in the aforementioned hospitals was done by calcu-
lating the mean.
This study was approved by the Ethics Committees 
of the four hospitals in the  Rede Sentinela. Patients were 
only included in the study aer they, or their legal repre-
sentative, signed the informed consent. Patient identifica-
tion data was kept confidential.
RESULTS
The characteristics of patients hospitalized for ADRs and 
pharmacologic group involved are shown in Table 1.
Total prevalence of ADRs was 0.56% (212/37,658); ad-
justed prevalence was 2.1% (212/10,276); the 212 patients 
hospitalized had a total of 316 reactions. Mean length of 
hospitalization was 12.3 ± 12.7 (1-77) days (2,490/202), with 
median of 8 days. A mean of 4,184 patients was hospitalized, 
although the denominator of exposed individuals was 10276 
patients due to the high frequency of patients admitted for 
elective surgeries, approximately 73% (10,276/37,658). Main 
organs and systems affected included: hematologic system, 
32.6% (103/316); skin, 18.7% (59/316); gastrointestinal sys-
tem, 14.6% (46/316); liver and gallbladder, 7% (22/316); 
Table 1 – Characteristics of patients hospitalized for ADRs 
and pharmacologic group involved, April to December 
2007, Salvador, BA, Brazil 
Variable n/N (%)
Gender  
Male 85/212 (40)
Female 127/212 (60)
Race  
Caucasian 83/212 (40.5)
Black 129/212 (59.5)
Age group  
0 to 19 years 61/212 (28.8)
20 to 39 years 33/212 (15.6)
40 to 59 years 52/212 (24.5)
Equal or greater than 60 years 66/212 (31.1)
Pharmacologic groups  
Antineoplastics 146/361 (40.4)
Antibiotics 28/361 (7.8)
Diuretics 26/361 (7.2)
Non-opioid analgesics 25/361 (6.9)
Antithrombotics 22/361 (6.1)
Steroid anti-inflammatories 18/361 (5)
Antimycobacterial 16/361 (4.4)
Non-steroidal anti-inflammatories 14/361 (3.9)
Others 66/361 (18.3)
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Variable n/N (%)
Type  
Recovery 192/212 (90.6)
Death from other causes 13/212 (6.1)
Unknown 6/212 (2.8)
Fatal 1/212 (0.5)
Sequela  
Yes 12/212 (5.7)
No 200/212 (94.3)
Table 2 – Outcomes of patients hospitalized for ADRs, April 
to December 2007, Salvador, Bahia, Brazil
central and peripheral nervous system, 5.7% (18/316); gen-
eral status, 5.1% (16/316); urinary system, 4.1% (13/316); 
cardiovascular system, 3.5% (11/316); endocrine system, 
2.8% (9/316); metabolism and nutrition, 2.2% (7/316); re-
spiratory system, 0.9% (3/316); eyes, skeletal musculature, 
and extra-cardiac vascular system, 0.6% (2/316); and other, 
0.9% (3/316). The main reactions presented by patients in-
cluded: pancytopenia, 9.2% (29/316); fever, 4.1% (13/316); 
thrombocytopenia, 4.1% (13/316); vomiting, 4.1% (13/316); 
skin rash, 3.8% (12/316); neutropenia, 3.8% (12/316); ane-
mia, 3.5% (11/316); and pruritus, 3.5% (11/316). Using 
methods to analyze the causality relationship, approximate-
ly 70% of ADRs were classified as certain or proven. Regard-
ing type, 80% (252/316) of cases were classified as A. Table 2 
describes the main outcomes.
As for the main pharmacological group (antineoplas-
tics), it reects both characteristics of the institutions and 
profiles of patients seen in these Reference Services. Reac-
tions to antineoplastics drugs are considered predictable but 
not preventable, due to their pharmacological effect, since 
these manifestations are the side effects of these treatments 
explained by exacerbation of their pharmacologic action. 
Additionally, antineoplastic treatment is performed in as-
sociation with other drugs that can increase the risk of de-
veloping ADRs19,20.
The main organs and systems involved in ADRs reect 
the main actions of the group of drugs used more oen by 
the population of this study. Hematologic ADRs, i.e., chang-
es in cell counts and other blood dyscrasias, are among the 
main problems related to antineoplastic therapy, being one 
of the causes of treatment discontinuation19,20. Since skin le-
sions are more visible and, occasionally, symptomatic, they 
are more commonly seen in emergency services, with a 
significant increase in morbidity and mortality, besides in-
creasing health care costs21.
Most ADRs was type A, which means they are dose-
dependent, with elevated morbidity and low mortality and, 
therefore, predictable, but not always preventable. This 
might explain the high recovery rate of most cases in this 
study. The only death observed was a case of stroke caused 
by warfarin use.
Casualty analysis by Naranjo, WHO, and European 
Union algorithms showed that most reactions were vali-
date as certain and likely, although  ADR diagnosis was 
confirmed in all cases. The explanation why algorithms do 
not demonstrate 100% certainty is due to the fact that some 
of the questions cannot always be applied to cases, as well 
as reect Health Services deficiencies (lack of serum levels, 
objective laboratorial demonstration, polypharmacy, and 
specific patient monitoring)22.
CONCLUSION
The prevalence of hospitalization for ADRs in the present 
study was similar to data in international literature, with only 
one death. Since this is the first national study with popula-
tional representation, it should be the basis for future studies.
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DISCUSSION
The prevalence of ADRs seen in this study was similar to 
that of international studies1-6. Literature data demon-
strate a wide variation in  hospitalization frequency  due to 
ADRs13,14. This can be explained by factors like the diversity 
of methodologies used in different studies and methods for 
detection of ADRs at the time of hospital admission, as well 
as establishing a cause, in addition to population and hospi-
tal characteristics. Other possible explanations include the 
lack of culture of notification of ADRs, lack of diagnosis of 
ADR in the hospitalization request form, and also the fact 
that ADRs are not always listed as a health problem.
The prevalence of hospitalization for ADRs in blacks 
was expected, as the population of Salvador is predomi-
nantly black (82.9%) (IBGE, 2009)15. On the other hand, 
the high prevalence of hospitalization for ADRs in Cau-
casians can be explained by the admission profile in the 
two philanthropic hospitals. Females were more prevalent, 
as they seek health care services more oã en than males16, 
and, therefore, they use more medications and are more 
prone to develop adverse reactions.
The age groups more oã en affected were similar to 
those reported in other studies, reinforcing young and el-
derly patients as risk groups for ADRs17. One of the expla-
nations for this is the existence of physiological conditions 
that determine pharmacokinetic and pharmacodynamic 
changes in these age groups18.
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